Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
By, Admin1 min read
Share
Caladrius Biosciences, Inc., and Cend Therapeutics, Inc., announced that the proposed merger of the two companies has closed following the approval of Caladrius
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
